Navigation Links
Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/5/2010

These two studies, one in type 1 diabetes patients and the other in type 2 patients, will each enroll approximately 110 patients. The primary endpoint will be a comparison of glycemic control, as assessed by the change in A1C from baseline.
  • An equity financing raised net proceeds of $60 million through a public offering of 8.3 million newly issued shares of common stock. The offering closed on September 14, 2010.
  • Halozyme completed its root cause investigation regarding HYLENEX manufacturing and has identified a corrective action plan and regulatory strategy to reintroduce HYLENEX to the market. We have been in communication with the U.S. Food and Drug Administration (FDA), and have provided them materials relating to the root cause and remediation plans.
  • Recently, Halozyme redirected its resources to concentrate on advancing its core proprietary programs through key clinical inflection points in 2011 and 2012, and to support its strategic alliances with Roche and Baxter. Halozyme will continue full development of its Phase 2 Ultrafast Insulin, Phase 1 PEGPH20, and preclinical HTI-501 programs, and has decreased research relating to the discovery and preclinical assessment of new compounds. This strategy resulted in reduction in the workforce of approximately 25 percent.
  • Baxter presented two posters with interim data from its Phase 3 clinical trial of HyQ at the European Society for Immunodeficiencies meeting in Istanbul, Turkey on October 6-9, 2010. HyQ is an immunoglobulin therapy facilitated subcutaneously by Halozyme's recombinant human hyaluronidase. Interim analyses showed that 28 out of 29 HyQ-treated study participants with primary immune deficiency were able to infuse immunoglobulin under the skin, using a single injection site, at infusion volumes, intervals and rates equivalent to their previous intravenous (IV) administration of immunoglobulin. 
  • Roche presented a poster of its Phase 1 clinical trial for Her
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
    2. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
    3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    4. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
    5. Halozyme Therapeutics to Host Research Day for Investors and Analysts
    6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
    8. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
    9. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    10. Halozyme Receives $5.5 Million Payment From Baxter
    11. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/23/2014)... September 23, 2014 Erlab , ... personnel since 1968 and Burdinola, supplier of laboratory furniture ... new filtered fume hood. , By integrating ... hood, Burdinola will now offer an innovative solution utilizing ... range of chemicals, best-in-class detection technology, and communication for ...
    (Date:9/23/2014)... 2014 ATCC, the premier global biological ... two important appointments to the senior leadership team. Barbie ... Strategy and Technology and Dr. Maryellen de Mars also ... Center. Both roles are new positions at ATCC. ... CEO at ATCC described the additions as part of ...
    (Date:9/23/2014)... 23, 2014 Follow us ... steady popularity the world over, due to its ... in the marketplace is expected to come from ... developing countries. Several sub-Saharan countries in the African ... already implemented genetically engineered crop production strategies. Rising ...
    (Date:9/23/2014)... 2014 News Facts , ... devoted to genome-based research for human health and disease, ... taking a bite out of oral cancer with its world-class ... India with the help of state-of-the-art solution ... (DDN). , To fuel its cutting-edge cancer research, the ...
    Breaking Biology Technology:Erlab Partners with Burdinola to Deliver an Innovative Filtered Fume Hood 2ATCC Announces New Appointments to its Leadership Team 2ATCC Announces New Appointments to its Leadership Team 3Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 4National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 2National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 3National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 4National Institute of Biomedical Genomics (NIBMG) Deploys DataDirect Networks Storage to Achieve Significant Performance Improvement in World-Class Genomics Research and Collaboration for Oral Cancer 5
    ... made tremendous scientific advances by dissecting apart the ... at the University of Wisconsin-Madison College of Engineering ... the pieces back together, mathematically. , John Yin, ... computer models of a relatively simple virus to ...
    ... SCOTTSDALE, Ariz., Feb. 6 Cancer Clinics of ... community oncologists, announced the completion of its 62nd ... leading oncology disease states at the 4th Annual ... oncology group is now fully prepared to launch ...
    ... LLC, a clinical-stage drug development company commercializing first-in-class ... completion of a $2.9 million private placement. ... and clinical programs for its lead drug compound, ... David G. Kalergis, Chief Executive Officer of Diffusion ...
    Cached Biology Technology:Mathematical models reveal how organisms transcend the sum of their genes 2Cancer Clinics of Excellence (CCE) Releases 62nd Evidence-Based Treatment Protocol 2Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida 2Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida 3
    (Date:9/23/2014)... tissues during the healing process, cells must be ... scientists believed this communication happened primarily through chemical ... the University of Pittsburgh have found that another ... not more crucial. The findings, published in this ... National Academy of Sciences , could lead to ...
    (Date:9/23/2014)... cow rumens and termite guts for microbes that can ... of next-generation biofuels, but some of the best microbial ... researchers report. , Their study , reported in ... , is the first to use biochemical approaches to ... can digest fiber, breaking it down into simple sugars ...
    (Date:9/23/2014)... vegetable consumption could be as good for your mental ... research, conducted by the University of Warwick,s Medical School ... published by BMJ Open focused on mental ... were consistently associated with an individual,s fruit and vegetable ... ate five or more portions of fruit and vegetables ...
    Breaking Biology News(10 mins):The mechanics of tissue growth 2Search for better biofuels microbes leads to the human gut 2Search for better biofuels microbes leads to the human gut 3Eating five a day may keep the blues away 2
    ... 11, 2012) The naked mole rat, a curiously strange, ... or rat. Scientists at The University of Texas Health Science ... continue to explore this mystery. On May 2 a ... machines for protein disposal called proteasome assemblies differ ...
    ... ON Lawson Health Research Institute announced today that it ... the Bill & Melinda Gates Foundation. Dr. Gregor Reid ... receive funding from the Gates Foundation. The research ... the nutrient rich plant called Moringa on the health outcomes ...
    ... A brain study in infant rats demonstrates that the ... new questions about using the first-line drug to treat ... Neurology EarlyView posted online May 11, researchers at ... drug phenobarbital given to rat pups about a week ...
    Cached Biology News:Scientists find differences in naked mole rat's protein disposers 2Lawson recieves Grand Challenges Explorations grant for groundbreaking research 2Study raises questions about use of anti-epilepsy drugs in newborns 2Study raises questions about use of anti-epilepsy drugs in newborns 3
    Mouse monoclonal [4i144] to HLA Class II DQ1 7 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 2 Antigen DQ1,7....
    ASCIZ...
    Goat polyclonal to CHMP5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-NKDGVLVDEFGLPQ, corresponding to C terminal amino acids 202-215 of Human CHMP5 Entrez GeneID: ...
    ...
    Biology Products: